Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Resource type
Journal Article
Authors/contributors
- Russo, Domenico (Author)
- Schmitt, Michael (Author)
- Pilorge, Sylvain (Author)
- Stelljes, Matthias (Author)
- Kawakita, Toshiro (Author)
- Teal, Valerie L. (Author)
- Haber, Barbara (Author)
- Bopp, Charlene (Author)
- Dadwal, Sanjeet S. (Author)
- Badshah, Cyrus (Author)
Title
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Publication
The Lancet Haematology
Publisher
Elsevier
Date
2024-02-01
Volume
11
Issue
2
Pages
e127-e135
Journal Abbr
The Lancet Haematology
Accessed
5/19/24, 8:51 AM
PMID
38142695
ISSN
2352-3026
Short Title
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection
Language
English
Library Catalog
Citation
Russo, D., Schmitt, M., Pilorge, S., Stelljes, M., Kawakita, T., Teal, V. L., Haber, B., Bopp, C., Dadwal, S. S., & Badshah, C. (2024). Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Haematology, 11(2), e127–e135. https://doi.org/10.1016/S2352-3026(23)00344-7
ORGANISMS
HEME-ONC AND CELLULAR THERAPIES
Link to this record